Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-EN Version v15-FR
Language English French
Date Updated 2021-03-08 2021-01-27
Drug Identification Number 02239834 02239834
Brand name LUPRON DEPOT LUPRON DEPOT
Common or Proper name Lupron depot 11.25mg Lupron depot 11.25mg
Company Name ABBVIE CORPORATION ABBVIE CORPORATION
Ingredients LEUPROLIDE ACETATE LEUPROLIDE ACETATE
Strength(s) 11.25MG 11.25MG
Dosage form(s) POWDER FOR SUSPENSION, SUSTAINED-RELEASE POWDER FOR SUSPENSION, SUSTAINED-RELEASE
Route of administration INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1 syringe (11.25mg) 1 syringe (11.25mg)
ATC code L02AE L02AE
ATC description HORMONES AND RELATED AGENTS HORMONES AND RELATED AGENTS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2020-07-14 2020-07-14
Actual start date 2020-07-14 2020-07-14
Estimated end date 2021-03-31 2021-03-31
Actual end date 2021-03-05
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments We have been working with the manufacturing facility to increase production of LUPRON DEPOT and we will continue to distribute supplies as they become available. As production of LUPRON DEPOT continues to increase, we expect inventory of all formulations to stabilize shortly. AbbVie wishes to assure you that we are your primary source of accurate and timely information related to our inventory shortage. The shortage is temporary, and the safety and efficacy of LUPRON DEPOT were not compromised. We have been working with the manufacturing facility to increase production of LUPRON DEPOT and we will continue to distribute supplies as they become available. As production of LUPRON DEPOT continues to increase, we expect inventory of all formulations to stabilize shortly. AbbVie wishes to assure you that we are your primary source of accurate and timely information related to our inventory shortage. The shortage is temporary, and the safety and efficacy of LUPRON DEPOT were not compromised.
Health Canada comments